Robert J. Jones's research while affiliated with University of Glasgow and other places

... An increased level of BTK expression is associated with a phenotype of bladder cancer cells with a higher tendency toward invasion and metastasis [111]. A phase Ib/II study of ibrutinib (BTK inhibitor) and weekly paclitaxel in 29 patients as a second/third line of treatment showed 26% ORR [112]. ...

... More recently, phosphate in urine from patients with bladder cancer was associated with greater toxicity and altered cell proliferation [40]. As previously mentioned, phosphate is dysregulated in CKD, and a higher risk of bladder cancer is associated with CKD in non-dialysis patients [41]. ...

... Multivariate analysis revealed the negative and positive predictive values of p-Akt and c-kit expression respectively with regards to overall survival. Moreover, c-kit expression was predictive of benefit from everolimus, and c-MET expression correlated with a poorer response to everolimus or sunitinib [83]. ...

... As an illustration, accounting for drug acquisition, delivery, and management of toxicities, a 6 month course of adjuvant FOLFOX chemotherapy costs in excess of 10,000 US dollars (USD) per patient [4,5]. Strategies to reduce AC utilisation, such as shortening duration of oxaliplatinbased AC from 6 to 3 months, has been projected to result in healthcare system savings of 3.6 to 61.4 million USD over a 5 year period depending on the country [6]. Another strategy to reduce costs is the use of molecular and genomic biomarkers that allows more precise identification of patients at high risk of recurrence that would most likely benefit from AC, reducing overtreatment by avoiding AC in patients who would least benefit [7][8][9][10]. ...

... We use a newly established, unique CRC dataset, which links demographic data to the Scottish Cancer Registry and routinely collected hospital admissions data. Full details of the linkage and creation of this source dataset are described elsewhere [24]. Public Health Scotland's (PHS) Data Quality Assurance team carry out regular data accuracy audits on national datasets. ...

... Just a few decades ago, clinical investigators and physicians were often advised to refrain from engaging in oncology due to its complexity and the discouraging clinical outcomes it yielded. Additionally, conducting cancer research required significant financial investment and relied on patients dedicating their time and effort (96). Currently, the primary challenge lies in the development of fundamental research on cancer prevention and treatment to impede the occurrence of new cases and reduce the global incidence of cancer. ...

... C.R. Hanna та співавт. [58] опублікували узагальнені відомості щодо ставлення клініцистів до використан-ня НДПТ при COVID-19, сфокусувавшись на обмеженнях зазначеного лікувального підходу. Дослідники зазначають, що хоча інфраструктура ПТ добре розвинена в багатьох країнах, проте не завжди наявні логістичні зв'язки з підрозділами інтенсивної терапії, тому можливості для лікування додаткових пацієнтів, які не мають раку, можуть бути обмеженими. ...

... Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients with different tumor types [4][5][6][7][8], including BC [9][10][11][12]. Currently, the detection of ctDNA can be based on two approaches: the tumor-informed approach, which requires the initial genomic profiling of the primary tumor, and the tumor-agnostic approach, which is independent of the genomic knowledge of the patient's prior tumor. ...

... Six large studies (each >1000 patients), using data from the US Veteran's Health Administration (VHA) [7,8], US Flatiron electronic medical record (EMR) [9], French National Health System [10], and Taiwan National Health Insurance databases [11,12], demonstrated statistically significant detriment in OS for abiraterone compared with enzalutamide in this population. Among studies with smaller sample sizes (100-1000 patients), one reported a significantly reduced OS with abiraterone versus enzalutamide [13] and eight found comparable OS for 1L abiraterone and enzalutamide [14][15][16][17][18][19][20][21]. Of note, a non-significant trend for worse survival with abiraterone versus enzalutamide was observed in five of these studies [14,17,18,20,21]. ...

... A comprehensive clinical history, along with physical examination and specific tests should be carried out in order to screen for CV risk factors and end-organ damage [32,33]. Additionally, an electrocardiogram and echocardiogram should be conducted when drugs with potential cardiac toxicity have been prescribed. ...